CO5580823A2 - Amidas de acido antranilico y su uso como inhibidores de tirosina-cinasa del receptor de vegf - Google Patents
Amidas de acido antranilico y su uso como inhibidores de tirosina-cinasa del receptor de vegfInfo
- Publication number
- CO5580823A2 CO5580823A2 CO04043909A CO04043909A CO5580823A2 CO 5580823 A2 CO5580823 A2 CO 5580823A2 CO 04043909 A CO04043909 A CO 04043909A CO 04043909 A CO04043909 A CO 04043909A CO 5580823 A2 CO5580823 A2 CO 5580823A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- amidas
- lower alkyl
- kinase inhibitors
- vegf receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
Abstract
1.- Una amida de ácido antranílico de la fórmula I: en donde:R1 representa H o alquilo inferior, R2 representa H o alquilo inferior, R3 representa perfluoroalquilo inferior, y X es O ó S, o un N-óxido o un tautómero de la misma, o una sal de esta amida de ácido antranílico, su N-óxido o su tautómero.2.- Una amida de ácido antranílico de la fórmula I de acuerdo con la reivindicación 1, en donde:R1 representa H o alquilo inferior, R2 representa H o alquilo inferior, R3 representa trifluorometilo, y X es O,o un N-óxido o un tautómero de la misma,o una sal de esta amida de ácido antranílico, su N-óxido o su tautómero.3.- Una amida de ácido antranílico de la fórmula I de acuerdo con la reivindicación 1, en donde:R1 representa H o metilo, R2 representa H o metilo, R3 representa trifluorometilo, y X es O, o un tautómero de la misma, o una sal de esta amida de ácido antranílico o su tautómero.4.- Una amida de ácido antranílico de la fórmula I de acuerdo con la reivindicación 1, seleccionada a partir de:2-[[6-metoxi-3-piridinil]metil]amino-N-[3-(trifluorometil) fenil]benzamida, sal de clorhidrato, 2-[[6-metoxi-3-piridinil]metil]amino-N-[2-metil-1-3-(trifluoro-metil)fenil]benzamida,2-[[(1,6-dihidro-6-oxo-3-piridinil)metil]amino]-N-[3-(trifluorometil)fenil]benzamida, y 2-[[(1,6-dihidro-6-oxo-3-piridinil)metil]amino]-N-[2-metil-3-(trifluorometiI)fenil]-benzamida, o un N-óxido o un tautómero de la misma, o una sal de esta amida de ácido antranílico, su N-óxido o su tautómero.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0126902.6A GB0126902D0 (en) | 2001-11-08 | 2001-11-08 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5580823A2 true CO5580823A2 (es) | 2005-11-30 |
Family
ID=9925448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO04043909A CO5580823A2 (es) | 2001-11-08 | 2004-05-12 | Amidas de acido antranilico y su uso como inhibidores de tirosina-cinasa del receptor de vegf |
Country Status (28)
Country | Link |
---|---|
US (2) | US7091224B2 (es) |
EP (1) | EP1446382B1 (es) |
JP (1) | JP2005511602A (es) |
KR (1) | KR100602977B1 (es) |
CN (1) | CN1300113C (es) |
AT (1) | ATE496889T1 (es) |
AU (1) | AU2002351909B2 (es) |
BR (1) | BR0213970A (es) |
CA (1) | CA2463968C (es) |
CO (1) | CO5580823A2 (es) |
DE (1) | DE60239073D1 (es) |
ES (1) | ES2360283T3 (es) |
GB (1) | GB0126902D0 (es) |
HR (1) | HRP20040411A2 (es) |
IL (1) | IL161747A0 (es) |
MX (1) | MXPA04004391A (es) |
NO (1) | NO327231B1 (es) |
NZ (1) | NZ532590A (es) |
PE (1) | PE20030714A1 (es) |
PL (1) | PL368416A1 (es) |
PT (1) | PT1446382E (es) |
RU (1) | RU2318811C2 (es) |
SA (1) | SA02230412B1 (es) |
TW (1) | TWI260222B (es) |
UA (1) | UA77446C2 (es) |
WO (1) | WO2003040102A1 (es) |
YU (1) | YU36004A (es) |
ZA (1) | ZA200402940B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7307088B2 (en) * | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
DE10327719A1 (de) * | 2003-06-13 | 2005-01-20 | Schering Ag | VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone |
US7202260B2 (en) | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
EP1568368A1 (en) * | 2004-02-26 | 2005-08-31 | Schering Aktiengesellschaft | Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor |
EP1655295A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
AU2005312721B9 (en) | 2004-12-07 | 2012-08-02 | Toyama Chemical Co., Ltd. | Novel anthranilic acid derivative or salt thereof |
US7547782B2 (en) * | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
CN101323629B (zh) * | 2007-02-16 | 2011-08-17 | 江苏正大天晴药业股份有限公司 | 4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-甲基磷酸二乙酯 |
CN102131782B (zh) | 2008-08-27 | 2014-07-30 | 利奥制药有限公司 | 作为vegf-2受体和蛋白酪氨酸激酶抑制剂的吡啶衍生物 |
JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
GB201322538D0 (en) | 2013-06-21 | 2014-02-05 | Immusmol Sas | Method for detecting small molecules in a sample |
CN107954893A (zh) * | 2017-11-28 | 2018-04-24 | 兰州纬寰生物科技有限公司 | 邻氨基苯甲酰胺衍生物及制备方法和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
-
2001
- 2001-11-08 GB GBGB0126902.6A patent/GB0126902D0/en not_active Ceased
-
2002
- 2002-07-11 UA UA20040403226A patent/UA77446C2/uk unknown
- 2002-11-02 SA SA02230412A patent/SA02230412B1/ar unknown
- 2002-11-06 TW TW091132669A patent/TWI260222B/zh active
- 2002-11-06 PE PE2002001080A patent/PE20030714A1/es not_active Application Discontinuation
- 2002-11-07 MX MXPA04004391A patent/MXPA04004391A/es active IP Right Grant
- 2002-11-07 PT PT02787595T patent/PT1446382E/pt unknown
- 2002-11-07 AT AT02787595T patent/ATE496889T1/de active
- 2002-11-07 WO PCT/EP2002/012444 patent/WO2003040102A1/en active IP Right Grant
- 2002-11-07 ES ES02787595T patent/ES2360283T3/es not_active Expired - Lifetime
- 2002-11-07 EP EP02787595A patent/EP1446382B1/en not_active Expired - Lifetime
- 2002-11-07 JP JP2003542148A patent/JP2005511602A/ja active Pending
- 2002-11-07 BR BR0213970-7A patent/BR0213970A/pt not_active IP Right Cessation
- 2002-11-07 CN CNB028222091A patent/CN1300113C/zh not_active Expired - Fee Related
- 2002-11-07 NZ NZ532590A patent/NZ532590A/en not_active IP Right Cessation
- 2002-11-07 RU RU2004117543/04A patent/RU2318811C2/ru not_active IP Right Cessation
- 2002-11-07 PL PL02368416A patent/PL368416A1/xx not_active Application Discontinuation
- 2002-11-07 YU YU36004A patent/YU36004A/sh unknown
- 2002-11-07 KR KR1020047007040A patent/KR100602977B1/ko not_active IP Right Cessation
- 2002-11-07 US US10/494,591 patent/US7091224B2/en not_active Expired - Fee Related
- 2002-11-07 IL IL16174702A patent/IL161747A0/xx unknown
- 2002-11-07 AU AU2002351909A patent/AU2002351909B2/en not_active Ceased
- 2002-11-07 DE DE60239073T patent/DE60239073D1/de not_active Expired - Lifetime
- 2002-11-07 CA CA2463968A patent/CA2463968C/en not_active Expired - Fee Related
-
2004
- 2004-04-19 ZA ZA200402940A patent/ZA200402940B/en unknown
- 2004-05-07 HR HR20040411A patent/HRP20040411A2/hr not_active Application Discontinuation
- 2004-05-12 CO CO04043909A patent/CO5580823A2/es not_active Application Discontinuation
- 2004-05-26 NO NO20042187A patent/NO327231B1/no not_active IP Right Cessation
-
2006
- 2006-03-14 US US11/374,720 patent/US7482369B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5580823A2 (es) | Amidas de acido antranilico y su uso como inhibidores de tirosina-cinasa del receptor de vegf | |
BR0009507A (pt) | Derivados de ftalazina para o tratamento de doenças inflamatórias | |
BRPI0418939A (pt) | derivados de nicotinamida e sua utilização como agentes terapêuticos | |
HRP20050309A2 (en) | Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | |
PT1236726E (pt) | Derivados de triazaespiro[5.5]undecano e farmacos que os contem como ingrediente activo | |
PT1378510E (pt) | Derivados de triazaespiro [5.5] undecano e farmacos que os contem como componentes activos | |
ATE453646T1 (de) | 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren | |
MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
MX2010002396A (es) | Metodos para administrar n-(5-ter-butil-isoxazol-3-il)-n?-{4-[7-(2 -morfolin-4-il-etoxi)imidazo[2, 1-b][1,3]benzotiazol-2-il] fenil} urea para tratar enfermedaes proliferativas. | |
NZ602948A (en) | Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders | |
BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
MY136322A (en) | Anthranilic acid amides and pharmaceutical use thereof | |
PE20040916A1 (es) | Diamidas de acido pirimidin-4,6-dicarboxilico como inhibidores selectivos de mmp-13 | |
ECSP045092A (es) | Amidas de acido antranilico y su uso como inhibidores de tirosina-cinasa del receptor de vegf | |
BR0317292A (pt) | Derivados de amida de ácido antranìlico e seu uso farmacêutico | |
UY27534A1 (es) | Amidas de ácido antranílico y uso farmacológico de las mismas. | |
TH88080A (th) | แอนทรานิลิกแอซิดเอไมด์และการใช้งานทางเภสัชกรรมของมัน | |
TH88080B (th) | "แอนทรานิลิกแอซิดเอไมด์และการใช้งานทางเภสัชกรรมของมัน" | |
TH58670B (th) | อนุพันธ์ 2-อะมิโน-3-(แอลคิล)-พิริมิโดน | |
EA201990188A1 (ru) | Производные 5,7-дигидропирролопиридина | |
TH158464A (th) | สารยับยั้งไพริดิลออกซีอินโดลของ vegf-r2 และการใช้งานของพวกมัน สำหรับการบำบัดโรค |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |